Search Results

AI is changing the nature of leadership in biopharma. Here’s how executives can not only adapt, but lead the way.

Petra Acquisition, Inc. announced that it has entered into certain backstop agreements and forward share purchase agreements for up to $12 million in connection with its proposed business combination with Revelation Biosciences, Inc., a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease.

Revelation Biosciences, Inc. and Petra Acquisition, Inc. announced they have entered into a definitive merger agreement for a business combination that will result in Revelation becoming a publicly traded company.

Rakovina Therapeutics Inc. announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to its Scientific Advisory Board.

Petra Pharma Corporation (“Petra”), a leader in phosphoinositide (PI) signaling pathway inhibition, today announces the appointment of Albert S. Yu, M.D. to Chief Medical Officer (CMO) and Clive Bertram to Head of Corporate Development.

Deal expands Petra’s portfolio, accelerating progress to Phase 2 clinical stage company

Petra Pharma to harness Evotec’s indigo platform to accelerate its lead programme through IND filing.